A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis

Advances in Therapy

Volumn 30, Issue 8, 2013, Pages 748-762

  Tin Tin Htar, Myint ^a   Madhava, Harish ^b   Balmer, Paul ^b   Christopoulou, Dina ^b   Menegas, Damianos ^a   Bonnet, Eric ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

7 Valent pneumococcal conjugate vaccine; Direct vaccine impact; Indirect vaccine impact; Pneumococcal meningitis; Vaccine impact

Indexed keywords

HUMANS; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME;

EID: 84894359471     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0051-2     Document Type: Review

References (40)

1. Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis. 2008;46(11):1664-72 (Epub 2008/04/25).
2. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902 (Epub 2009/09/ 15).
3. McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect. 2007;135(4): 644-56 (Epub 2006/09/09).
4. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis. 2010;10(1):32-42 (Epub 2010/02/05).
5. van Hoek AJ, Andrews N, Waight PA, George R, Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PloS one. 2012;7(7):e39150 (Epub 2012/07/21).
6. Neuman HB, Wald ER. Bacterial meningitis in childhood at the Children's Hospital of Pittsburgh: 1988-1998. Clin Pediatr (Phila). 2001;40(11):595-600 (Epub 2002/01/05).
7. Levy C, Bingen E, Aujard Y, et al. Surveillance network of bacterial meningitis in children, 7 years of survey in France. Arch Pediatr. 2008;15(Suppl 3):S99-104 (Epub 2009/03/14. Observatoire national des meningites bacteriennes de l'enfant en France : resultats de 7 annees d'etude).
8. Chavez-Bueno S, McCracken GH Jr. Bacterial meningitis in children. Pediatr Clin North Am. 2005;52(3):795-810 (vii. Epub 2005/06/01).
9. Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127-51 (Epub 2013/02/12).
10. EUVac.Net. Pneumococcal vaccination (PCV) overview in European countries. 2012. http:// www.euvac.net/graphics/euvac/vaccination/pcv.html. Accessed 24 Oct 2012.
11. Rendi-Wagner P, Paulke-Korinek M, Kundi M, et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Vaccine. 2009;27(30):3963-8 (Epub 2009/04/28).
12. Hanquet G, Lernout T, Vergison A, et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29(16):2856-64 (Epub 2011/02/24).
13. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine. 2010;28(14):2642-7 (Epub 2010/01/26).
14. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16(5):816-23 (Epub 2010/04/23).
15. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48(1):57-64 (Epub 2008/11/28).
16. Aristegui J, Bernaola E, Pocheville I, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26(5):303-10 (Epub 2007/04/26).
17. Calbo E, Diaz A, Canadell E, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12(9): 867-72.
18. Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15(11): 1013-9.
19. Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13(35). pii:18962 (Epub 2008/09/03).
20. Munoz-Almagro C, Jordan I, Gene A, Latorre C. Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-82 (Epub 2008/01/ 04).
21. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10): 760-8.
22. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(12):1569-76 (Epub 2007/05/23).
23. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18): 1737-46.
24. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41 (Epub 2009/12/02).
25. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244-56 (Epub 2009/01/16).
26. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine. 2005;23(48-49):5464-73 (Epub 2005/09/ 29).
27. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802-8 (Epub 2012/09/25).
28. Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013;56(5):e59-67 (Epub 2012/11/17).
29. Levy C, Varon E, Bingen E, et al. Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30(2):168-70 (Epub 2011/02/08).
30. Pichon B, Ladhani SN, Slack MP, et al. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol. 2013;51(3):820-7 (Epub 2012/12/28).
31. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24(1): 17-23.
32. Prymula R, Chlibek R, Ivaskeviciene I, et al. Paediatric pneumococcal disease in Central Europe. Eur J Clin Microbiol Infect Dis. 2011;30(11):1311-20 (Epub 2011/06/15).
33. Hausdorff W. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr. 2002;161(2):S135-9.
34. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122-40 (Epub 2000/01/05).
35. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100-21 (Epub 2000/01/05).
36. de Aristegui Fernandez J, Corretger Rauet JM, Garcia Martin F, et al. Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine (La enfermedad neumococica y su prevencion. Vacuna neumococica conjugada heptavalente). An Esp Pediatr. 2002;56(1):79-90 (Epub 2002/01/17).
37. Alexandre C, Dubos F, Courouble C, et al. Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatr. 2010;99(11):1686-90 (Epub 2010/07/ 16).
38. Casado-Flores J, Rodrigo C, Aristegui J, Martinon JM, Fenoll A, Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27(11):1020-2 (Epub 2008/10/11).
39. Dubos F, Marechal I, Husson MO, et al. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child. 2007;92(11):1009-12 (Epub 2007/07/13).
40. Salleras L, Dominguez A, Ciruela P, Izquierdo C, Borras E, Grupo de Trabajo del Sistema de Notificacion Microbiologica de C. Impact of 7-valent pneumococcal conjugate vaccination in a population with low to intermediate vaccination levels. Enferm Infecc Microbiol Clin. 2009;27(5):275-7 (Epub 2009/04/24. Impacto de la vacuna neumococica conjugada heptavalente en una poblacion con valores bajos-intermedios de vacunacion).